US Markets

Israel's Healthy.io raises $60 mln, gets FDA ok for urine test

Israel's Healthy.io said on Thursday it raised $60 million in funding and received clearance from the U.S. Food and Drug Administration for its smartphone-based urine albumin test to aid in diagnosing chronic kidney disease.

TEL AVIV, Sept 12 (Reuters) - Israel's Healthy.io said on Thursday it raised $60 million in funding and received clearance from the U.S. Food and Drug Administration for its smartphone-based urine albumin test to aid in diagnosing chronic kidney disease.

The funding round was led by Corner Ventures with

participation by Joy Capital Ventures and previous investors Ansonia Holdings, Aleph and Samsung NEXT. The company has raised $95 million to date.

The funds will be used to accelerate Healthy.io’s global expansion and product development.

"The smartphone has the potential to be the great equalizer of healthcare," said Yonatan Adiri, founder and CEO of Healthy.io.

This is the company's second FDA clearance. Last year it received clearance for its at-home, smartphone-based urinalysis test kit and now has a partnership with Boots UK, placing its test kits in hundreds of pharmacies.

(Reporting by Tova Cohen; Editing by Steven Scheer)

((tova.cohen@thomsonreuters.com; +972-9-899-0222; Reuters Messaging: tova.cohen.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest US Markets Videos

    #TradeTalks: How Investors Start to Position Themselves in front of the Election

    WealthWise Financial CEO Loreen Gilbert joins Jill Malandrino on Nasdaq #TradeTalks to discuss what she is watching in the markets as investors start to position themselves in front of the election.

    Sep 10, 2020

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More